BIIB.MX Biogen Inc

Healthcare Pharmaceuticals Mexican Exchange
4,690 MXN
Close of Nov 7, 2026
2,790 4,690
Market cap
MXN 693B
P/E
115.0x
P/B
1.97x
ROE
2.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BIIB.MX undervalued?

Graham number

The Graham number of Biogen Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biogen Inc fundamental analysis

No fundamental analysis for Biogen Inc yet.

Biogen Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimuma…

Full company profile